Navigation Links
Telik Announces Preclinical Presentations at AACR Annual Meeting
Date:4/7/2008

PALO ALTO, Calif., April 7, 2008 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced that four abstracts highlighting results from its Research and Development programs will be presented at the 99th annual meeting of the American Association for Cancer Research (AACR) in San Diego.
Details of the presentations are as follows:

-- Identification and Characterization of Novel Tyrosine Kinase Inhibitors

Targeting Vascular Endothelial Growth Factor Receptor 2; Sunday, April

13, 2008, 1:00 - 5:00pm; Experimental and Molecular Therapeutics 10;

Abstract # 1439

-- Mechanism of Induction of Apoptosis by TLK199 (Telintra(R)) in Human

Leukemia Cell Lines; Monday, April 14, 2008, 8:00am - 12noon;

Experimental and Molecular Therapeutics 10; Abstract # 2270

-- Identification of a Novel Class of Nonpeptidyl Small-Molecule

Inhibitors of the Human Proteasome; Monday, April 14, 2008,

1:00 - 5:00pm; Experimental and Molecular Therapeutics 28;

Abstract # 3271

-- Target-Related Affinity Profiling (TRAP(R)): Efficient Cancer Drug

Discovery at Telik; Tuesday, April 15, 2008; 1:00 - 5:00pm; Cancer

Chemistry 11; Abstract # 4754

Telik, Inc. of Palo Alto, CA, is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA, a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates.

TELIK, the Telik logo, TELCYTA, TELINTRA and TRAP are trademarks or registered trademarks of Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Telik Reports Positive Results From Phase 1 Dose-Escalation Study of TELINTRA Tablets in Myelodysplastic Syndrome
2. DARA Announces Information in Compliance with NASDAQ Rules
3. Journey Lite of Thousand Oaks Announces Special Spring Price Discount In Response to Effects of Softening Economy on Patients Pocketbooks
4. VA Announces SGLI and VGLI Premium Reductions
5. London Luxury LLC Announces Exclusive Partnership with Cupron, Inc., to Develop Innovative Copper-Infused Bed and Bath Products
6. Boston Scientific Announces Appointment of Timothy Pratt as General Counsel
7. Accuri Cytometers Announces Commercial Launch of Revolutionary Accuri C6 Flow Cytometer(TM) System
8. Haemacure Announces Details of its Annual General and Special Meeting of Shareholders
9. QED International Associates Announces Changes to the HealthShares(TM) Cardio Devices Index (As Revised)
10. Smart Balance Announces Sales Organization Appointments
11. Global Action Board of Directors Announces Addition of Newest Member, Robert Hernreich
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... Toronto, ON (PRWEB) , ... April 29, 2016 ... ... GlutenFreeCoupons.ca and the Canadian Celiac Association (CCA), is pleased to announce the launch ... about gluten-free products, nutritional articles, recipes, and more. The purpose of the ...
(Date:4/29/2016)... ... ... For those who skip meals occasionally (which is pretty much everyone), two ... new lifestyle diet tips offered by nutritionists Pam Bonney and Priya Lawrence of Tried ... Bonny and Lawrence noted that because proper nutrition, including water, provides energy during the ...
(Date:4/29/2016)... ... 2016 , ... The infertility specialists at HRC Fertility/Orange County (HRC/OC) -- Dr. ... Potter -- are proud of the recent release of their 2014 in vitro fertilization ... published the latest verified data for 375 U.S. member clinics. *Preliminary data shows ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... for Duchenne muscular dystrophy, and funding for Duchenne research, participated in the April ... the Sarepta Therapeutic’s novel Duchenne drug eteplirsen. The meeting at the Marriott Conference ...
(Date:4/29/2016)... ... April 29, 2016 , ... Yisrayl Hawkins, Pastor and Overseer at ... of adding BC and AD, saying it is time to set the record straight. ... Yisrayl says this simply cannot possibly be true and offers explanation. , “To start ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... April 27, 2016 ... the  "Global Anesthesia Disposables Market 2016-2020"  report ... ) ,The global anesthesia disposables market ... of 4.03% during the period 2016-2020.  ... threat to patients, safety. Organizations like the ...
(Date:4/27/2016)... SAN FRANCISCO , April 27, 2016 /PRNewswire/ ...  is expected to reach USD 2.06 billion by ... View Research, Inc. Increasing consumer awareness towards a ... over the next seven years.      ... Improper diet intake coupled with rising health treatment ...
(Date:4/26/2016)... -- Hill-Rom Holdings, Inc. (NYSE: HRC ) invites ... Bank 41 st Annual Health Care Conference on Wednesday, ... are invited to listen to the live discussion via the ... at http://edge.media-server.com/m/p/mr4uxgas . A recorded replay of the discussion ... event and accessible at the links above until August 1, ...
Breaking Medicine Technology: